4552.T Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 09:15):

Stats
Šios dienos apimtis	800 300
Vidutinė apimtis	720 063
Rinkos kapitalizacija	99.47B
EPS	¥0 ( 2024-01-25 )
Kita pelno data	( ¥16.69 ) 2024-05-08
Last Dividend	¥10.00 ( 2023-03-30 )
Next Dividend	¥0 ( N/A )
P/E	18.62
ATR14	¥0.642 (0.08%)

Tūris Koreliacija

Ilgas: -0.14 (neutral)

Trumpas: 0.13 (neutral)

Signal:(54.951) Neutral

JCR Pharmaceuticals Co., Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

JCR Pharmaceuticals Co., Koreliacija - Valiuta/Žaliavos

-0.36
( neutral )

-0.33
( neutral )

-0.31
( neutral )

-0.24
( neutral )

-0.16
( neutral )

0.32
( neutral )

JCR Pharmaceuticals Co., Finansinės ataskaitos

Annual	2022
Pajamos:	¥34.34B
Bruto pelnas:	¥25.46B (74.13 %)
EPS:	¥30.34

FY	2022
Pajamos:	¥34.34B
Bruto pelnas:	¥25.46B (74.13 %)
EPS:	¥30.34

FY	2022
Pajamos:	¥51.08B
Bruto pelnas:	¥40.62B (79.52 %)
EPS:	¥117.26

FY	2021
Pajamos:	¥30.09B
Bruto pelnas:	¥22.27B (74.03 %)
EPS:	¥55.81

Financial Reports:

No articles found.

JCR Pharmaceuticals Co., Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
¥10.00 (N/A)	¥0 (N/A)	¥10.00 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)	¥0 (N/A)

JCR Pharmaceuticals Co., Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.40 - Stable (12.03%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	¥1.250	2007-09-25
Last Dividend	¥10.00	2023-03-30
Next Dividend	¥0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	30	--
Total Paid Out	¥100.88	--
Avg. Dividend % Per Year	0.00%	--
Score	3.56	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.40
Div. Directional Score	7.52	--

Next Divdend (Est)
(2024-09-30)

¥0 Estimate 0.00 %

Dividend Stability

0.09 Very Bad

Dividend Score

3.56

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for JPX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
8343.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
7727.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
6901.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
6262.T	Ex Dividend Knight	2023-09-28	Annually	0.00%
4974.T	Ex Dividend Junior	2024-03-28	Annually	0.00%
4187.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
3388.T	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
2462.T	Ex Dividend Knight	2023-11-29	Semi-Annually	0.00%
9972.T	Ex Dividend Junior	2023-11-29	Annually	0.00%
8963.T	Ex Dividend Junior	2023-12-28	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.130	1.500	7.41	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0522	1.200	8.26	9.91	[0 - 0.3]
returnOnEquityTTM	0.0987	1.500	-0.0142	-0.0213	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.801	0.800	6.00	4.80	[1 - 3]
quickRatioTTM	1.084	0.800	8.33	6.67	[0.8 - 2.5]
cashRatioTTM	0.573	1.500	7.93	10.00	[0.2 - 2]
debtRatioTTM	0.227	-1.500	6.22	-9.33	[0 - 0.6]
interestCoverageTTM	105.82	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0.419	-1.500	8.33	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.748	1.000	0.861	0.861	[0.2 - 0.8]
operatingProfitMarginTTM	0.189	1.000	8.21	8.21	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.242	1.000	9.77	9.77	[0.2 - 2]
assetTurnoverTTM	0.402	0.800	-0.650	-0.520	[0.5 - 2]
Total Score				10.65

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	18.54	1.000	8.23	0	[1 - 100]
returnOnEquityTTM	0.0987	2.50	-0.00912	-0.0213	[0.1 - 1.5]
freeCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	2.51	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	45.13	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.168	1.500	-2.21	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.136	1.000	9.10	0	[0.1 - 0.5]
Total Score				4.40

JCR Pharmaceuticals Co.,

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.